PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Neuron2 citationsOpen Access

Large-scale CSF and plasma proteomics reveal immune, synaptic, and extracellular matrix disruptions across neurodegenerative diseases

View Full Paper
MAM. Ashraf AliJTJigyasha TimsinaYXYing Xu

Key Points

  • The research aims to identify shared and disease-specific molecular features in neurodegenerative diseases using proteomics.
  • Analyzed cerebrospinal fluid and plasma proteomes from 2,705 and 3,009 samples respectively.
  • Conducted pathway analyses to assess immune-related processes and disease-specific pathways.
  • Developed predictive models with high accuracy for identifying neurodegenerative diseases.
  • CSF exhibited more disease-associated proteins compared to plasma.
  • Alzheimer's disease and dementia with Lewy bodies showed significant cross-tissue similarities.
  • Dysregulation of immune pathways and specific pathways validated across neurodegenerative diseases.

Abstract

Summary Neurodegenerative diseases (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), share overlapping clinical and pathological features. We analyzed cerebrospinal fluid (CSF) and plasma proteomes from 2,705 and 3,009 samples, respectively, across these NDs, identifying disease-specific and shared molecular signatures. CSF showed more disease-associated proteins than plasma, with AD and DLB exhibiting the strongest cross-tissue similarity. Pathway analyses revealed shared dysregulation of immune-related processes in CSF and plasma across the NDs, as well as disease-specific impairment of glycosylation and apoptotic pathways in AD; ATF4 and PERK signaling in PD; fibroblast growth factor receptor (FGFR) and interleukin signaling in DLB; and glycoprotein hormones disruption in FTD. We developed disease-specific predictive models showing high accuracy (area under the curve AUC: 0.81–0.95 in CSF and 0.80–0.89 in plasma). These findings reveal distinct and convergent mechanisms across NDs, highlighting potential biomarkers and pathways for diagnostic and therapeutic strategies in neurodegeneration.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ali et al. (2026) studied this question.

synapsesocial.com/papers/69ccb5f716edfba7beb87b05https://doi.org/10.1016/j.neuron.2026.02.035
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests2024 · 445 citations
  2. 2Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders2003 · 225 citations
  3. 3Harmonization of CSF and imaging biomarkers in Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification2023 · 50 citations
  4. 4Fibroblast Growth Factor Signalling in the Diseased Nervous System2021 · 128 citations
  5. 5Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies2007 · 434 citations